vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $17.3M, roughly 1.3× Valens Semiconductor Ltd.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -42.2%, a 49.5% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 8.1%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
CUE vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $17.3M |
| Net Profit | $1.6M | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | 9.0% | -46.4% |
| Net Margin | 7.2% | -42.2% |
| Revenue YoY | 1292.3% | 8.1% |
| Net Profit YoY | 116.7% | 29.3% |
| EPS (diluted) | $0.05 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | — | ||
| Q3 25 | $2.1M | $17.3M | ||
| Q2 25 | $3.0M | $17.1M | ||
| Q1 25 | $421.0K | $16.8M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $3.3M | $16.0M | ||
| Q2 24 | $2.7M | $13.6M | ||
| Q1 24 | $1.7M | — |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-7.4M | $-7.3M | ||
| Q2 25 | $-8.5M | $-7.2M | ||
| Q1 25 | $-12.3M | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.7M | $-10.4M | ||
| Q2 24 | $-10.2M | $-8.9M | ||
| Q1 24 | $-12.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | -353.4% | -46.4% | ||
| Q2 25 | -292.3% | -43.3% | ||
| Q1 25 | -2921.4% | -56.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -264.2% | -76.3% | ||
| Q2 24 | -390.6% | -69.2% | ||
| Q1 24 | -737.8% | — |
| Q4 25 | 7.2% | — | ||
| Q3 25 | -346.6% | -42.2% | ||
| Q2 25 | -287.1% | -42.1% | ||
| Q1 25 | -2911.4% | -49.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -259.6% | -64.6% | ||
| Q2 24 | -382.7% | -65.2% | ||
| Q1 24 | -719.1% | — |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | $-0.07 | ||
| Q2 25 | $-0.09 | $-0.07 | ||
| Q1 25 | $-0.17 | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | $-0.10 | ||
| Q2 24 | $-0.20 | $-0.08 | ||
| Q1 24 | $-0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $108.8M |
| Total Assets | $42.2M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | $93.5M | ||
| Q2 25 | $27.5M | $102.7M | ||
| Q1 25 | $13.1M | $112.5M | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | $133.1M | ||
| Q2 24 | $30.0M | $105.9M | ||
| Q1 24 | $41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | — | ||
| Q3 25 | $13.2M | $108.8M | ||
| Q2 25 | $18.2M | $116.5M | ||
| Q1 25 | $6.6M | $128.6M | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $25.4M | $147.0M | ||
| Q2 24 | $21.6M | $153.5M | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $42.2M | — | ||
| Q3 25 | $31.6M | $136.7M | ||
| Q2 25 | $40.7M | $144.8M | ||
| Q1 25 | $22.3M | $154.6M | ||
| Q4 24 | $32.2M | — | ||
| Q3 24 | $44.8M | $171.9M | ||
| Q2 24 | $42.3M | $175.8M | ||
| Q1 24 | $54.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-4.9M |
| FCF MarginFCF / Revenue | — | -28.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-9.0M | $-4.7M | ||
| Q2 25 | $-3.4M | $-211.0K | ||
| Q1 25 | $-8.2M | $-7.6M | ||
| Q4 24 | $-36.3M | — | ||
| Q3 24 | $-7.5M | $3.0M | ||
| Q2 24 | $-10.0M | $-225.0K | ||
| Q1 24 | $-9.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.9M | ||
| Q2 25 | $-3.4M | $-330.0K | ||
| Q1 25 | $-8.3M | $-8.0M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | $2.2M | ||
| Q2 24 | $-10.0M | $-460.0K | ||
| Q1 24 | $-9.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | -116.5% | -1.9% | ||
| Q1 25 | -1976.7% | -47.3% | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | 14.0% | ||
| Q2 24 | -376.2% | -3.4% | ||
| Q1 24 | -573.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.9% | 0.7% | ||
| Q1 25 | 35.6% | 2.1% | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | 4.5% | ||
| Q2 24 | 0.4% | 1.7% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
VLN
Segment breakdown not available.
